Our findings strongly suggested that AGNHW pre-treatment has the potential to exert a protective effect in vivo against ischemic stroke or other relative neuronal diseases, and inactivation of GSK-3β could serve as a novel therapeutic target for the protection against stroke, which support further clinical studies for disease prevention. The gene discussed is GSK3B; the disease is stroke disorder.